Transfusion Research Center, Belgian Red Cross Flanders, Ghent, Belgium; Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Transfusion Research Center, Belgian Red Cross Flanders, Ghent, Belgium.
J Thromb Haemost. 2023 Aug;21(8):2223-2235. doi: 10.1016/j.jtha.2023.03.020. Epub 2023 Mar 29.
A disintegrin and metalloprotease 17 (ADAM17) catalyzes platelet glycoprotein (GP) Ibα ectodomain shedding, thereby releasing glycocalicin in plasma. The spatiotemporal control over the enzyme-substrate interaction and the biological consequences of GPIbα shedding are poorly understood.
This study aimed to determine the spatiotemporal control over GPIbα shedding by ADAM17.
Transmission electron microscopy with immunogold staining, immunoprecipitation, and quantitative western blotting were used.
Immunogold staining showed that all ADAM17 antigen is expressed intracellularly, irrespective of platelet activation. ADAM17 clustered in patches on a tortuous membrane system different from α- and dense granules. Mild activation by platelet adhesion to immobilized fibrinogen did not cause GPIbα shedding, whereas strong and sustained stimulation using thrombin and collagen (analogs) did. Glycocalicin release kinetics was considerably slower than typical hemostasis, starting at 20 minutes and reaching a plateau after 3 hours of strong stimulation. Inhibition of the ADAM17 scissile bond specifically in GPIbα receptors that reside on the platelet's extracellular surface did not prevent shedding, which is in line with the strict intracellular location of ADAM17. Instead, shedding was restricted to a large GPIbα subpopulation that is inaccessible on resting platelets but becomes partially accessible following platelet stimulation. Furthermore, the data show that proteinaceous, water-soluble ADAM17 inhibitors cannot inhibit GPIbα shedding, whereas membrane permeable small molecule ADAM inhibitors can.
The data show that platelets harbor 2 distinct GPIbα subpopulations: one that presents at the platelet's surface known for its role in primary hemostasis and one that provides substrate for proteolysis by ADAM17 with kinetics that suggest a role beyond hemostasis.
解整合素金属蛋白酶 17(ADAM17)催化血小板糖蛋白(GP)Ibα 细胞外结构域的脱落,从而将糖蛋白 Gc 释放到血浆中。该酶-底物相互作用的时空控制以及 GPIbα 脱落的生物学后果尚不清楚。
本研究旨在确定 ADAM17 对 GPIbα 脱落的时空控制。
使用透射电子显微镜免疫金染色、免疫沉淀和定量 Western 印迹。
免疫金染色显示,所有 ADAM17 抗原均在细胞内表达,与血小板激活无关。ADAM17 在不同于α颗粒和致密颗粒的曲折膜系统上呈斑片状聚集。血小板黏附到固定纤维蛋白原上的轻度激活不会导致 GPIbα 脱落,而使用凝血酶和胶原(类似物)进行强烈和持续的刺激则会导致脱落。糖蛋白 Gc 的释放动力学比典型的止血过程慢得多,从 20 分钟开始,在强烈刺激 3 小时后达到平台期。仅在位于血小板细胞外表面的 GPIbα 受体上抑制 ADAM17 的裂解键并不能阻止脱落,这与 ADAM17 的严格细胞内位置一致。相反,脱落仅限于一个大的 GPIbα 亚群,该亚群在静息血小板上无法接近,但在血小板刺激后部分可接近。此外,这些数据表明,蛋白质、水溶性 ADAM17 抑制剂不能抑制 GPIbα 脱落,而膜通透的小分子 ADAM 抑制剂可以。
数据表明,血小板包含 2 种不同的 GPIbα 亚群:一种位于血小板表面,以其在初级止血中的作用而闻名,另一种为 ADAM17 的蛋白水解提供底物,其动力学表明其作用超出止血范围。